TABLE 1.
Angiography and Infusion Summary
| Subject | Age | Weight | Infusion concentration/volume | Cell infusion duration; Location | Control injection duration; Location | Angiographic result | Procedure outcomes |
|---|---|---|---|---|---|---|---|
| Canine 1 | 10 mo 13 d | 35 kg (77 lbs) | 2 × 106 cells/20 mL | 32 min; L ICA | 17 min; R ICA | No angiographic occlusions | No complications |
| Canine 2 | 8 mo 6 d | 27.5 kg (60.5 lbs) | 1 × 107 cells/20 mL | 40 min 50 s; L ICA | 15 min 28 s; R ICA | No angiographic occlusions | No complications |
| Canine 3 | 9 mo 22 d | 28.3 kg (61.8 lbs) | 2 × 107 cells/20 mL | 22 min 21 s; L ICA | 20 min 34 s; R ICA | No angiographic occlusions | No complications |
| Canine 4 | 10 mo 26 d | 28.8 kg (63.5 lbs) | 1 × 108 cells/20 mL | 21 min; R ICA | 17 min; L ICA | No angiographic occlusions | No complications |
| Canine 5 | 8 mo 22 d | 33.1 kg (72.9 lbs) | 1 × 108 cells/20 mL | 21 min 34 s; L PCA | 18 min; R PCA | No angiographic occlusions | Technical difficulty in PCA access |
| Canine 6 | 9 mo 14 d | 32.7 kg (72.1 lbs) | 1 × 108 cells/10 mL | 11 min 26 s; L PCA | 10 min 12 s; R PCA | No angiographic occlusions | Basal cistern/perivascular SAH, no stroke or other complications |
| Canine 7 | 8 mo 15 d | 27.6 kg (60.8 lbs) | Lumi Particles; Positive control #1 | R PCA | L PCA no injection | Slowed flow in R PCA without occlusion | Basal cistern/perivascular SAH, no stroke or other complications |
| Canine 8 | 9 mo 27 d | 33.6 kg (74.1 lbs) | Lumi Particles; Positive control #2 | R ICA | No injection | Complete occlusion of R ICA, stagnant LICA flow | Numerous particles found in meningeal vessels and brain on both hemispheres. |
| Canine 9 | 8 mo 20 d | 26.0 kg (57.3 lbs) | 1 × 108 cells/10 mL Survival #1 |
R ICA | L ICA | No angiographic occlusions | No complications |
| Canine 10 | 9 mo 2 d | 29.3 kg (64.6 lbs) | 1 × 108 cells/10 mL Survival #2 |
L ICA | R ICA | No angiographic occlusions | No complications |
Angiographic result is summarized in comparison to baseline angiography prior to infusion. Technical notes or complications are also described. Full procedural reports are available in Supplemental data. For all ICA injections, a Synchro2 microwire (0.014”, Stryker Neurovascular) over an Echelon 14 microcatheter was used. PCA injections were more technically challenging. When inaccessible with the Synchro2/Echelon 14 system, a Marathon microcatheter (Medtronic) over a Mirage microwire (.008”, Medtronic) was used.